Within the subgroup of patients with EGFR amplification, patients with EGFRvIII-positive GBM showed worse survival [median PFS, 1.63 vs. 3.03 months (P=0.01); median OS, 3.27 vs. 5.57 months (P=0.08)], indicating that the type of EGFR mutation may determine the outcome of GBM patients treated with cetuximab.93 This evidence concerns the gene EGFR and glioblastoma.